That $95M Mer­ck gam­ble to ac­quire cCAM? It didn’t pay off.

When Mer­ck $MRK ac­quired cCAM Bio­ther­a­peu­tics in Is­rael in the sum­mer of 2015, R&D chief Roger Perl­mut­ter and his crew were in­trigued by the po­ten­tial …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA